IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
POTOMAC, MD / / March 20, 2025 / IGC Pharma, Inc. ('IGC', or the 'Company') (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. This expansion marks a key milestone in IGC Pharma's strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and expanding the Company's clinical footprint.
Hamilton Health Sciences is one of Canada's leading academic and research hospitals. The CALMA trial at HHS will be led by Dr. Alexandra Papaioannou, a distinguished geriatrician and Executive Director of HHS' Geras Centre for Aging Research, whose expertise in aging, frailty, and dementia will play a critical role in the trial's success.
'We are excited to welcome Hamilton Health Sciences as a site in the CALMA trial,' said Ram Mukunda, CEO of IGC Pharma. 'Their world-class expertise in geriatric care and dementia research aligns with our mission to develop safe and effective therapies for Alzheimer's patients. Expanding the trial to this prestigious institution not only strengthens our study but also enhances patient access, accelerating our efforts to bring IGC-AD1 to market and deliver value for shareholders.'
'Agitation is a significant challenge for Alzheimer's patients, their families, and caregivers,' said Dr. Alexandra Papaioannou. 'By participating in the CALMA trial, we aim to contribute to the development of urgently needed therapies to improve the quality of life for individuals living with this disease. We look forward to advancing research that has the potential to make a meaningful impact.'
About IGC-AD1 and the CALMA Trial
IGC-AD1 is IGC Pharma's investigational cannabinoid-based therapy currently in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study (CALMA) evaluating its safety and efficacy for treating agitation in Alzheimer's dementia. Agitation affects up to 76% of Alzheimer's patients, often leading to increased hospitalization and caregiver burden. IGC-AD1 acts as a partial CB1 receptor agonist with anti-neuroinflammatory properties, targeting key pathways involved in neuroinflammation, oxidative stress, and neurotransmitter imbalances.
With multiple trial sites now active across the U.S. and Canada, IGC Pharma remains focused on accelerating patient enrollment and generating data that could support regulatory approval and commercialization of IGC-AD1.
For more information on the CALMA trial, visit: ClinicalTrials.gov.
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia ('CALMA') associated with Alzheimer's ( clinicaltrials.gov, IGC Pharma Phase II). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 32 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions. The Company operates a wellness brand offering scientifically formulated products under the brand Holiby™ and as white-labeled formulations.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ('SEC') filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
(203) 972-9200
SOURCE: IGC Pharma, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
It's official: Your diet is making you depressed, according to science
Skipping dessert really can leave you down in the dumps. No one who's been on a diet has ever said, 'I love calorie restriction,' but a new study has found a not-so-surprising link between low-cal eating and depression. And some people have it worse than others. 3 Researchers found that men and those whose BMI classified them as overweight were particularly susceptible to diet-linked depression. Studio Romantic – The dietary habits and depressive symptoms of 28,000 US adults were analyzed for the study, published in BMJ Nutrition Prevention & Health. Of these adults, 29% had a healthy weight, 33% were deemed overweight, and 38% were considered obese. The dietary patterns were divided into four categories: calorie-restrictive, nutrient-restrictive (AKA low in fat), sugar, salt, or carbs, established dietary pattern, or not on a diet at all. The majority of participants, 87%, did not follow any specific diet, 8% followed a calorie-restrictive diet, 3% opted for nutrient restriction, and 2% followed an established dietary pattern. Using questionnaires from the US National Health and Nutrition Examination Survey, researchers found that 8% of participants reported depressive symptoms. Those on calorie or nutrient-restrictive diets exhibited higher scores of emotional and physical distress than their cohorts who were not on a specific diet, suggesting that unsupervised restrictive diets may negatively affect mental health. Researchers found that men and those whose BMI classified them as overweight were particularly susceptible to diet-linked depression. 3 Besides affecting your quality of life and relationships, depression can raise the risk of heart disease, diabetes, stroke, dementia, Alzheimer's disease, anxiety disorders, and substance abuse. bravissimos – 'The findings suggest caution with overly restrictive or unbalanced diets, particularly for people already experiencing weight-related stress or challenges,' said lead study author Dr. Venkat Bhat, psychiatrist, clinician-researcher, and director of the Interventional Psychiatry Program at St. Michael's Hospital and University of Toronto. Researchers found that the quality of diet had a direct bearing on depression risk. Those whose diet was rife with ultra-processed foods (UPFs) were more likely to report higher levels of depression. Recent research revealed that 60% of Americans' daily caloric intake comes from ultra-processed foods. UPFs often contain high levels of sodium, refined sugars, cholesterol-spiking fats and other lab-based ingredients. A 2023 study from the Harvard T.H. Chan School of Public Health found that people who consume nine or more servings of UPFs a day have a 50% higher risk of developing depression than those who eat four or fewer daily servings. 3 Previous studies have established that a Mediterranean diet rich in fruit, veggies, nuts, fish, and plants can slash depression risk by a third. Eightshot Images – In contrast, this latest study revealed that those who followed a Mediterranean diet exhibited lower rates of depression. Previous studies have established that a Mediterranean diet rich in fruit, veggies, nuts, fish, and plants can slash depression risk by a third. In a 2023 Gallup poll, 29% of US adults reported having been diagnosed with depression at some point in their lifetime, while 17.8% of Americans said they have depression or are being treated for it. Besides affecting your quality of life and relationships, depression can raise the risk of heart disease, diabetes, stroke, dementia, Alzheimer's disease, anxiety disorders and substance abuse. Given the results of this study, Bhat suggests dieters abstain from strict caloric restriction and instead opt for,' balanced, sustainable dietary changes that meet nutritional needs.' Researchers note that their findings only reveal associations, not definitive data. Further, due to the survey format, there's no way to verify that participants truly adhere to caloric restriction. Still, Bhat and his team are hopeful that future studies will continue to examine the relationship between calorie restriction and mental health.
Yahoo
2 hours ago
- Yahoo
The LGL Group, Inc. Adds Over-Subscription Privilege to Outstanding Warrants, Files Post-Effective Amendment to the Related Registration Statement
Orlando, Florida--(Newsfile Corp. - June 5, 2025) - The LGL Group, Inc. (NYSE American: LGL) (NYSE American: LGL WS) ("LGL Group" or the "Company") today announced that is has added an Over-Subscription Privilege to its outstanding warrants to purchase common stock which were originally issued as a dividend to LGL Group stockholders on November 16, 2020 (the "Warrants"). The Company will file with the Securities and Exchange Commission (the "SEC") a post-effective amendment to its related registration statement on Form S-1 that, once declared effective, will permit holders to exercise the Warrants up and until to their expiration at the close of business on November 16, 2025, a Sunday, which allows holders to exercise the Warrants by the close of business on November 17, 2025 (the "Expiration Date"). Current Exercise Price of Warrants As a result of the previously announced downward adjustment of the exercise price triggered by the spinoff of M-tron Industries, Inc., five (5) Warrants are exercisable to purchase one share of common stock at an exercise price of $4.75. Addition of Over-Subscription Privilege The Company has amended the warrant agreement to add an Over-Subscription Privilege that will from and after close of business on October 16, 2025 (the "Over-Subscription Commencement Date") until the Expiration Date allow warrant holders to subscribe for additional shares of common stock that remain unsubscribed as a result of any unexercised Warrants. The total number of shares of common stock that will be available to all holders who exercise their Warrants and elect the Over-Subscription Privilege will be the number of shares which are not subscribed for as of the Expiration Date pursuant to the basic warrant exercise rights of all holders. Holders that exercise the Warrants prior to the Over-Subscription Commencement Date will not be entitled to subscribe for additional shares pursuant to the Over-Subscription Privilege. Further information concerning how to exercise LGL Group Warrants can be found on the Warrant FAQ page of the Company's website at None of the Company, its board of directors or employees has made or is making any representation or recommendation to any holder of the Warrants as to whether to exercise or refrain from exercising any Warrants. Pending Registration LGL Group will file with the SEC a post-effective registration statement on Form S-1 (No. 333-158319) that includes a prospectus relating to the offering of the shares of common stock issuable upon exercise of the Warrants. The securities being registered may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Copies of the prospectus for the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at Warrant Agent Computershare Inc. and its wholly-owned subsidiary, Computershare Trust Company, N.A. (together "Computershare"), serve as the Company's warrant agent. All holders of LGL Group's warrants should direct all questions concerning the Warrants to Computershare at: By telephone (within the U.S., U.S. territories and Canada): 1-800-546-5141 By telephone (outside the U.S., U.S. territories and Canada): 1-781-575-2765 If delivering by U.S. mail: Computershare Trust Company, N.A.c/o Voluntary Corporate ActionsP.O. Box 43011Providence, RI 02940-3011 If delivering by courier: Computershare Trust Company, N.A.c/o Voluntary Corporate Actions150 Royall Street, Suite VCanton, MA 02021 The warrant FAQs relating to their original issuance and amendments made to date can be found: About The LGL Group, Inc. The LGL Group, Inc. ("LGL," "LGL Group," or the "Company") is a holding company engaged in services, merchant investment and manufacturing business activities. Precise Time and Frequency, LLC ("PTF") is a globally positioned producer of industrial Electronic Instruments and commercial products and services. Founded in 2002, PTF operates from our design and manufacturing facility in Wakefield, Massachusetts. Lynch Capital International LLC is focused on the development of value through investments. LGL Group was incorporated in 1928 under the laws of the State of Indiana, and in 2007, the Company was reincorporated under the laws of the State of Delaware as The LGL Group, Inc. We maintain our executive offices at 2525 Shader Road, Orlando, Florida 32804. Our telephone number is (407) 298-2000. Our Internet address is LGL Group common stock and warrants are traded on the NYSE American under the symbols "LGL" and "LGL WS," respectively. LGL Group's business strategy is primarily focused on growth through expanding new and existing operations across diversified industries. The Company's engineering and design origins date back to the early 1900s. In 1917, Lynch Glass Machinery Company ("Lynch Glass"), the predecessor of LGL Group, was formed and emerged in the late 1920s as a successful manufacturer of glass-forming machinery. Lynch Glass was then renamed Lynch Corporation ("Lynch") and was incorporated in 1928 under the laws of the State of Indiana. In 1946, Lynch was listed on the "New York Curb Exchange," the predecessor to the NYSE American. The Company has a had a long history of owning and operating various business in the precision engineering, manufacturing, and services sectors. Cautionary Note Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as those pertaining to the Company's financial condition, results of operations, business strategy and financial needs. All statements other than statements of current or historical fact contained in this press release are forward-looking statements. The words "believe," "expect," "anticipate," "should," "plan," "will," "may," "could," "intend," "estimate," "predict," "potential," "continue" or the negative of these terms and similar expressions, as they relate to LGL Group, are intended to identify forward-looking statements. These forward-looking statements are largely based on current expectations and projections about future events and financial trends that may affect the financial condition, results of operations, business strategy and financial needs of the Company. They can be affected by inaccurate assumptions, including the risks, uncertainties and assumptions described in the filings made by LGL Group with the Securities and Exchange Commission ("SEC"), including those risks set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025. In light of these risks, uncertainties and assumptions, the forward-looking statements in this press release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this press release. These forward-looking statements speak only as of the date of this press release. LGL Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. No Offer or Solicitation This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy common stock of the Company or any other securities and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. ### Contact: The LGL Group, To view the source version of this press release, please visit
Business Wire
2 hours ago
- Business Wire
The Arena Group Regains Compliance with NYSE American Continued Listing Standards
NEW YORK--(BUSINESS WIRE)--As of June 4, 2025, The Arena Group Holdings, Inc. (NYSE American: AREN) ('The Arena Group' or the 'Company'), a technology platform and media company home to brands including TheStreet, Parade, Men's Journal, and Athlon Sports, received formal notification from NYSE American that it had regained compliance with the NYSE American's continued listing standards set forth in Part 10 of the NYSE American Company Guide as outlined in the Company's October 8, 2024 press release. This resolution was achieved in advance of the April 2026 deadline set by NYSE American to regain compliance. The Arena Group received formal notification from NYSE American that it had regained compliance with the NYSE American's continued listing standards in advance of April 2026 deadline. Share 'We are pleased to have regained compliance with the NYSE American continued listing standards in such a short time,' said Paul Edmondson, CEO of The Arena Group. 'We believe this reflects not only the market-driven stock appreciation, but also our strengthened financial position and three consecutive profitable quarters for the first time in company history. We believe we are well-positioned to maintain profitability throughout 2025.' Arena's common stock will continue to be traded on the NYSE American, subject to its continued compliance with all applicable listing standards Arena previously disclosed the details of the NYSE American notification HERE. For additional information, please refer to the Company's filings with the Securities and Exchange Commission at or visit the Company's investor relations page at About The Arena Group The Arena Group (NYSE American: AREN) is an innovative technology platform and media company with a proven cutting-edge playbook that transforms media brands. Our unified technology platform empowers creators and publishers with tools to publish and monetize their content, while also leveraging quality journalism of anchor brands like TheStreet, Parade, Men's Journal, Athlon Sports, Surfer, Powder and more to build their businesses. The company aggregates content across a diverse portfolio of brands, reaching over 100 million users monthly. Visit us at and discover how we are revolutionizing the world of digital media. Forward Looking Statements This press release includes statements that constitute forward-looking statements. Forward-looking statements may be identified by the use of words such as 'forecast,' 'guidance,' 'plan,' 'estimate,' 'will,' 'would,' 'project,' 'maintain,' 'intend,' 'expect,' 'anticipate,' 'prospect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'believe,' 'continue,' 'opportunity,' 'potential,' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, and include, for example, statements related to the Company's anticipated future expenses and investments, business strategy and plans, expectations relating to its industry, market conditions and market trends and growth, market position and potential market opportunities, and objectives for future operations. These forward-looking statements are based on information available at the time the statements are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the ability of the Company to expand its verticals; the Company's ability to grow its subscribers; the Company's ability to grow its advertising revenue; general economic uncertainty in key global markets and a worsening of global economic conditions or low levels of economic growth; the effects of steps that the Company could take to reduce operating costs; the remaining effects of the COVID-19 pandemic and impact on the demand for the Company products; the inability of the Company to sustain profitable sales growth; circumstances or developments that may make the Company unable to implement or realize the anticipated benefits, or that may increase the costs, of its current and planned business initiatives; and those factors detailed by the Company in its public filings with the SEC, including its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Should one or more of these risks, uncertainties, or facts materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by the forward-looking statements contained herein. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
